Paion AG gave its beleaguered investors a little autumnal cheer by raising hopes that its clot-busting stroke drug Desmoteplase might return to the clinic, despite a Phase III clinical trial miss earlier this year that precipitated a share price plunge. (BioWorld International)

SAN DIEGO - Chances are the biotech community in Southern California is not reading this article. More likely, they are still glued to their TV sets, trying to determine whether or not their homes are safe, as they have since the fires began. (BioWorld Today)